Correlative Analyses
tumor
TUMOR
Peripheral blood was evaluated for mRNA signals corresponding to cMET CAR T cells using RT-PCR at the following timepoints: preinfusion safety visit; on the day of each infusion before and 1 hour after infusion; at 4 hours following the first infusion; on day +1; on day +25. As described previously (Formalin-fixed paraffin-embedded tissue sections from preinfusion and postinfusion tumor samples were analyzed by IHC using the Leica Bond III instrument. Slides were pretreated with Bond ER2 solution for 20 minutes at 100°C. Antibodies to CD3 (Leica, PA0122), CD4 (Biocare, API3209AA), CD8 (Dako, M7103), Ki67 (Dako IR626), Foxp3 (BioLegend, 320102), phosphorylated S6 (pS6), PD1 (Abcam, ab52587), PD-L1 (Cell Signaling Technology, 15165BF), CD163 (Leica, CD163-L-CE), granzyme B (Leica, PA0291), and cMET (Ventana, 790-4430) were used as described previously (